Trial Profile
A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs ABSK 091 (Primary)
- Indications Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Lung-MAP
- 25 May 2021 Status changed from active, no longer recruiting to completed.
- 10 Jun 2019 Results published in the Journal of Thoracic Oncology
- 13 Dec 2017 Planned End Date changed from 1 Jun 2020 to 1 Apr 2022.